ArticleBMC palliative care2025
Temporal trends and determinants of inpatient palliative care utilization among hospitalized patients with acute myeloid leukemia: a retrospective cross-sectional study.
Article in BMC palliative care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute myeloid leukemia (AML) remains an aggressive malignancy, despite advancements in diagnosis and treatment. Early integration of palliative care has been shown to alleviate symptom burden and enhance quality of life among patients and their caregivers. However, palliative care remains underutilized, especially in hematologic malignancies. This study aims to determine the rate of inpatient palliative care utilization among hospitalized patients with AML and to identify predictors of inpatient palliative care utilization.
methodsThis retrospective study utilized data extracted from the National Inpatient Sample database from 2016 to 2020. Adult patients diagnosed with acute myeloid leukemia (AML) and recipients of palliative care services were identified through the International Classification of Diseases, 10th Revision (ICD-10) coding system. Sociodemographic, hospital-related, and clinical characteristics were summarized using frequencies and percentages. Binary logistic regression analysis was performed to determine independent predictors of inpatient palliative care utilization.
resultsThere were 121,892 hospital admissions of patients with a primary diagnosis of AML. Of these, 460 patients (0.3%) received inpatient palliative care services. Among those receiving palliative care, most were aged ≥ 65 years (59.8%), male (53.3%), White (83.1%), and privately insured (40.2%). In multivariable analysis, older age (OR 1.57; 95% CI 1.23-2.01; p < 0.001), private insurance (OR 1.43; 95% CI 1.33-1.53; p < 0.001), receipt of chemotherapy or stem cell therapy (OR 4.13; 95% CI 3.28-5.20; p < 0.001), and inpatient mortality (OR 8.80; 95% CI 6.86-11.28; p < 0.001) were independently associated with increased palliative care utilization. While non-White race (OR 0.70; 95% CI 0.61-0.81; p < 0.001), treatment in certain hospital regions (OR 0.75; 95% CI 0.67-0.83; p < 0.001), and shorter length of stay (OR 0.60; 95% CI 0.47-0.76; p < 0.001) were associated with lower utilization.
conclusionInpatient palliative care remains markedly underutilized among patients with acute myeloid leukemia. Sociodemographic, economic, hospital, and clinical factors significantly influence its utilization. Addressing these disparities through targeted interventions and institutional policies may enhance palliative care integration, potentially improving symptom management, quality of life, and overall care outcomes for patients with AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.